Last updated on July 2018

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil - WF 97116


Brief description of study

This study is to compare the safety and effects of donepezil (Aricept) or if it decreases memory loss after receiving chemotherapy for breast cancer.

Detailed Study Description

A randomized, placebo controlled, double-blind, parallel group Phase 3 design will be used to assess the effect of 24 weeks of donepezil on cognitive function (memory) in breast cancer survivors who report having cognitive dysfunction and demonstrate memory impairment 1-5 year post chemotherapy. Patients who meet the eligibility criteria will be stratified by age (<50, 50-59, 60-69, 70) and randomized to donepezil or placebo with equal probability.

Clinical Study Identifier: NCT02822573

Contact Investigators or Research Sites near you

Start Over

Wake Forest School of Medicine

Winston-Salem, NC United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.